Xenograft or Cell Line | Length of CR1 | Survival after First Relapse | Current Clinical Status | VCR IC50 by MTT Assay | VCR IC50 by MS-5 Assay | Steady-State VCR Uptake | Polymerized Tubulin | ||
---|---|---|---|---|---|---|---|---|---|
mo. | nM | pmol/106 cells | % | ||||||
ALL-2 | 30 | 46 | DOD | 578 | 5.1 | 0.34 ± 0.13 | 8.5 ± 2.2 | ||
ALL-3 | 38 | 115* | CR2 | 1.6 | 1.3 | 0.91 ± 0.34 | 5.6 ± 1.9 | ||
ALL-4 | 10 | 1 | DOD | 4.0 | 5.3 | 1.1 ± 0.4 | 9.5 ± 1.3 | ||
ALL-7 | 7 | 6 | DOD | 3.5 | 3.6 | 1.2 ± 0.3 | 5.0 ± 2.3 | ||
ALL-8 | 17 | 1 | DOD | 0.18 | 16 | 0.63 ± 0.28 | 6.8 ± 2.3 | ||
ALL-10 | 85* | CR1 | 1.8 | 0.15 | 1.3 ± 0.3 | 3.0 ± 0.5 | |||
ALL-11 | 137* | CR1 | 398 | 4.2 | 0.48 ± 0.20 | 6.1 ± 0.8 | |||
ALL-16 | 120* | CR1 | 0.37 | 0.21 | 1.0 ± 0.4 | 4.2 ± 3.6 | |||
ALL-17 | 25 | 63* | CR2 | 5.9 | 14 | 1.9 ± 0.3 | 9.1 ± 3.0 | ||
ALL-19 | 4 | 7 | DOD | 5.3 | 81 | 1.8 ± 0.1 | 16.0 ± 2.4 | ||
VCR R | N.A. | N.A. | N.A. | 5,000 | N.D. | 0.16 ± 0.02 | 45.0 ± 1.5 | ||
CEM-WT | N.A. | N.A. | N.A. | 0.73 | N.D. | 2.8 ± 0.2 | 34.1 ± 0.7 |
CR1, alive in first complete remission; CR2, alive in second complete remission; DOD, dead of disease; N.A., not applicable; N.D., not done.
↵* No event (censored).